Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Min-Han Lin, David C Moses, Chih-Hua Hsieh, Shu-Chun Cheng, Yau-Hung Chen, Chiao-Yin Sun, Chi-Yuan Chou, Min-Han Lin, David C Moses, Chih-Hua Hsieh, Shu-Chun Cheng, Yau-Hung Chen, Chiao-Yin Sun, Chi-Yuan Chou
Abstract
Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in southern China in late 2002 and caused a global outbreak with a fatality rate around 10% in 2003. Ten years later, a second highly pathogenic human CoV, MERS-CoV, emerged in the Middle East and has spread to other countries in Europe, North Africa, North America and Asia. As of November 2017, MERS-CoV had infected at least 2102 people with a fatality rate of about 35% globally, and hence there is an urgent need to identify antiviral drugs that are active against MERS-CoV. Here we show that a clinically available alcohol-aversive drug, disulfiram, can inhibit the papain-like proteases (PLpros) of MERS-CoV and SARS-CoV. Our findings suggest that disulfiram acts as an allosteric inhibitor of MERS-CoV PLpro but as a competitive (or mixed) inhibitor of SARS-CoV PLpro. The phenomenon of slow-binding inhibition and the irrecoverability of enzyme activity after removing unbound disulfiram indicate covalent inactivation of SARS-CoV PLpro by disulfiram, while synergistic inhibition of MERS-CoV PLpro by disulfiram and 6-thioguanine or mycophenolic acid implies the potential for combination treatments using these three clinically available drugs.
Keywords: 6-Thioguanine; Disulfiram; MERS- and SARS-CoV; Mycophenolic acid; Papain-like protease; Synergistic inhibition.
Copyright © 2017 Elsevier B.V. All rights reserved.
Figures
References
- Bailey-Elkin B.A., Knaap R.C., Johnson G.G., Dalebout T.J., Ninaber D.K., van Kasteren P.B., Bredenbeek P.J., Snijder E.J., Kikkert M., Mark B.L. Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 2014;289:34667–34682.
- Bell R.G., Smith H.W. Preliminary report on clinical trials of antabuse. Can. Med. Assoc. J. 1949;60:286–288.
- Chan J.F., Chan K.H., Kao R.Y., To K.K., Zheng B.J., Li C.P., Li P.T., Dai J., Mok F.K., Chen H., Hayden F.G., Yuen K.Y. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J. Infect. 2013;67:606–616.
- Chen C.Z., Southall N., Galkin A., Lim K., Marugan J.J., Kulakova L., Shinn P., van Leer D., Zheng W., Herzberg O. A homogenous luminescence assay reveals novel inhibitors for giardia lamblia carbamate kinase. Curr. Chem. Genomics. 2012;6:93–102.
- Chen X., Chou C.Y., Chang G.G. Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme. Antivir. Chem. Chemother. 2009;19:151–156.
- Cheng K.W., Cheng S.C., Chen W.Y., Lin M.H., Chuang S.J., Cheng I.H., Sun C.Y., Chou C.Y. Thiopurine analogs and mycophenolic acid synergistically inhibit the papain-like protease of Middle East respiratory syndrome coronavirus. Antiviral Res. 2015;115:9–16.
- Chou C.Y., Chien C.H., Han Y.S., Prebanda M.T., Hsieh H.P., Turk B., Chang G.G., Chen X. Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus. Biochem. Pharmacol. 2008;75:1601–1609.
- Chou C.Y., Lai H.Y., Chen H.Y., Cheng S.C., Cheng K.W., Chou Y.W. Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease. Acta Crystallogr. Sect. D Biol. Crystallogr. 2014;70:572–581.
- Chou Y.W., Cheng S.C., Lai H.Y., Chou C.Y. Differential domain structure stability of the severe acute respiratory syndrome coronavirus papain-like protease. Arch. Biochem. Biophys. 2012;520:74–80.
- Clementz M.A., Chen Z., Banach B.S., Wang Y., Sun L., Ratia K., Baez-Santos Y.M., Wang J., Takayama J., Ghosh A.K., Li K., Mesecar A.D., Baker S.C. Deubiquitinating and interferon antagonism activities of coronavirus papain-like proteases. J. Virol. 2010;84:4619–4629.
- Copeland R. Wiley-VCH Inc; 2000. Enzymes: a Practical Introduction to Structure, Mechanism, and Data Analysis.
- Diaz-Sanchez A.G., Alvarez-Parrilla E., Martinez-Martinez A., Aguirre-Reyes L., Orozpe-Olvera J.A., Ramos-Soto M.A., Nunez-Gastelum J.A., Alvarado-Tenorio B., de la Rosa L.A. Inhibition of urease by disulfiram, an FDA-approved thiol reagent used in humans. Molecules. 2016;21
- Elliott J.H., McMahon J.H., Chang C.C., Lee S.A., Hartogensis W., Bumpus N., Savic R., Roney J., Hoh R., Solomon A., Piatak M., Gorelick R.J., Lifson J., Bacchetti P., Deeks S.G., Lewin S.R. Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV. 2015;2:e520–529.
- Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallogr. Sect. D Biol. Crystallogr. 2004;60:2126–2132.
- Frieman M., Ratia K., Johnston R.E., Mesecar A.D., Baric R.S. Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J. Virol. 2009;83:6689–6705.
- Galkin A., Kulakova L., Lim K., Chen C.Z., Zheng W., Turko I.V., Herzberg O. Structural basis for inactivation of Giardia lamblia carbamate kinase by disulfiram. J. Biol. Chem. 2014;289:10502–10509.
- Han Y.S., Chang G.G., Juo C.G., Lee H.J., Yeh S.H., Hsu J.T., Chen X. Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition. Biochemistry. 2005;44:10349–10359.
- Hilgenfeld R., Peiris M. From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antiviral Res. 2013;100:286–295.
- Kitson T.M. The effect of disulfiram on the aldehyde dehydrogenases of sheep liver. Biochem. J. 1975;151:407–412.
- Krampe H., Ehrenreich H. Supervised disulfiram as adjunct to psychotherapy in alcoholism treatment. Curr. Pharm. Des. 2010;16:2076–2090.
- Lee H., Lei H., Santarsiero B.D., Gatuz J.L., Cao S., Rice A.J., Patel K., Szypulinski M.Z., Ojeda I., Ghosh A.K., Johnson M.E. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARS-CoV. ACS Chem. Biol. 2015;10:1456–1465.
- Lee Y.M., Duh Y., Wang S.T., Lai M.M., Yuan H.S., Lim C. Using an old drug to target a new drug site: application of disulfiram to target the Zn-Site in HCV NS5A protein. J. Am. Chem. Soc. 2016;138:3856–3862.
- Lei J., Mesters J.R., Drosten C., Anemuller S., Ma Q., Hilgenfeld R. Crystal structure of the papain-like protease of MERS coronavirus reveals unusual, potentially druggable active-site features. Antiviral Res. 2014;109:72–82.
- Lin M.H., Chuang S.J., Chen C.C., Cheng S.C., Cheng K.W., Lin C.H., Sun C.Y., Chou C.Y. Structural and functional characterization of MERS coronavirus papain-like protease. J. Biomed. Sci. 2014;21:54.
- Lipsky J.J., Shen M.L., Naylor S. In vivo inhibition of aldehyde dehydrogenase by disulfiram. Chem. Biol. Interact. 2001;130–132:93–102.
- McCoy A.J., Grosse-Kunstleve R.W., Adams P.D., Winn M.D., Storoni L.C., Read R.J. Phaser crystallographic software. J. Appl. Crystallogr. 2007;40:658–674.
- Menachery V.D., Yount B.L., Jr., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A., Graham R.L., Scobey T., Ge X.Y., Donaldson E.F., Randell S.H., Lanzavecchia A., Marasco W.A., Shi Z.L., Baric R.S. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015;21:1508–1513.
- Menachery V.D., Yount B.L., Jr., Sims A.C., Debbink K., Agnihothram S.S., Gralinski L.E., Graham R.L., Scobey T., Plante J.A., Royal S.R., Swanstrom J., Sheahan T.P., Pickles R.J., Corti D., Randell S.H., Lanzavecchia A., Marasco W.A., Baric R.S. SARS-like WIV1-CoV poised for human emergence. Proc. Natl. Acad. Sci. U. S. A. 2016;113:3048–3053.
- Moore S.A., Baker H.M., Blythe T.J., Kitson K.E., Kitson T.M., Baker E.N. Sheep liver cytosolic aldehyde dehydrogenase: the structure reveals the basis for the retinal specificity of class 1 aldehyde dehydrogenases. Structure. 1998;6:1541–1551.
- Murshudov G.N., Skubak P., Lebedev A.A., Pannu N.S., Steiner R.A., Nicholls R.A., Winn M.D., Long F., Vagin A.A. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 2011;67:355–367.
- Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997;276:307–326.
- Paranjpe A., Zhang R., Ali-Osman F., Bobustuc G.C., Srivenugopal K.S. Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damage. Carcinogenesis. 2014;35:692–702.
- Perlman S., Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nat. Rev. Microbiol. 2009;7:439–450.
- Ratia K., Pegan S., Takayama J., Sleeman K., Coughlin M., Baliji S., Chaudhuri R., Fu W., Prabhakar B.S., Johnson M.E., Baker S.C., Ghosh A.K., Mesecar A.D. A noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication. Proc. Natl. Acad. Sci. U. S. A. 2008;105:16119–16124.
- Ratia K., Saikatendu K.S., Santarsiero B.D., Barretto N., Baker S.C., Stevens R.C., Mesecar A.D. Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc. Natl. Acad. Sci. U. S. A. 2006;103:5717–5722.
- Verma S., Dixit R., Pandey K.C. Cysteine proteases: modes of activation and future prospects as pharmacological targets. Front. Pharmacol. 2016;7:107.
- Yang X., Chen X., Bian G., Tu J., Xing Y., Wang Y., Chen Z. Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease. J. Gen. Virol. 2014;95:614–626.
- Yonetani T., Theorell H. Studies on liver alcohol hydrogenase complexes. 3. Multiple inhibition kinetics in the presence of two competitive inhibitors. Arch. Biochem. Biophys. 1964;106:243–251.
- Zaki A.M., van Boheemen S., Bestebroer T.M., Osterhaus A.D., Fouchier R.A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012;367:1814–1820.
- Zheng D., Chen G., Guo B., Cheng G., Tang H. PLP2, a potent deubiquitinase from murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res. 2008;18:1105–1113.
Source: PubMed